**A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy**

**WHO will take part in this study?**

The study is open to patients with triple-negative breast cancer (tumor has tested negative for estrogen receptors [ER-], progesterone receptors [PR-] and HER2 [HER2-]) that have received chemotherapy prior to surgery (neoadjuvant chemotherapy), then had surgery to remove the breast cancer, and viable tumor was still seen in the surgery specimen. This situation is associated with a high risk of metastatic recurrence of breast cancer, and better treatment strategies are sorely needed. Approximately 750 women and men will take part in this study. If you are not sure if you would qualify for this study, ask your physician.

**WHY consider participating in this study?**

Clinical studies are an important way to test the effectiveness of drugs for treating breast cancer. This trial is seeking to find out whether a platinum-based chemotherapy (in this case, cisplatin or carboplatin) after surgery may be a better treatment option, when compared with the currently used chemotherapy (capecitabine) for patients with triple-negative breast cancer (TNBC) who are at higher risk of their cancer coming back.

Chemotherapy drugs work in different ways to stop the growth of tumor cells, and it is not yet known whether the platinum drugs are more effective than capecitabine in treating patients with remaining TNBC. This trial will provide important information to help answer this question.

If you have triple-negative breast cancer, you may be eligible to participate in this study.
**WHAT does this study involve?**

This study enrolls patients with triple-negative breast cancer who have received neoadjuvant chemotherapy and have been found to have remaining disease in the breast at the time of surgery.

- This study offers treatment after surgery with additional chemotherapy (adjuvant chemotherapy). This additional chemotherapy is intended to impact any remaining cancer and help further prevent a future metastatic recurrence of the cancer.
- You will be assigned by chance to receive either ARM B or ARM C study medications. ARM B medication will be cisplatin or carboplatin (both are part of the platinum group of medications), and your physician will decide which option is better for you. ARM C medication is capecitabine (the chemotherapy usually given to patients with triple-negative disease needing further chemotherapy).
- This trial is seeking to find out whether one medication group has a better treatment outcome (hold off recurrence of breast cancer) and better side effect profile than the other group.
- The goal of this study is to get better outcomes for patients with triple-negative breast cancer and better inform physicians and patients when making treatment decisions.

**WHAT are the costs of taking part in this study?**

- You and/or your health plan or insurance company will need to pay some or all of the costs of treating your cancer in this study. Check with your health plan or insurance company to find out what they will pay for.
- For more information on insurance coverage and clinical trials, visit the National Cancer Institute (NCI) website at: [https://www.cancer.gov/about-cancer/treatment/clinical-trials/paying](https://www.cancer.gov/about-cancer/treatment/clinical-trials/paying) or call 1-800-4-CANCER (1-800-422-6237).

**IF you would like to know more**

- About the EA1131 study
  - Ask your doctor
  - Visit [www.ecog-acrin.org](http://www.ecog-acrin.org) and search EA1131, then select the link to EA1131. If you are seeking information about medical facilities where this trial is available, scroll down the page to Locations and Contacts
  - Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237)
- About clinical trials and general cancer information
  - Visit the NCI website at [www.cancer.gov](http://www.cancer.gov)